Subscribe to RSS
DOI: 10.1055/s-0042-1746462
Influence of therapy with Omalizumab in N-ERD patients on quality of life and sleep
Introduction Studies have shown that quality of sleep is impaired in patients with CRSwNP. The aim of the following study was to find out whether this symptom could be improved by therapy with Omalizumab.
Method 16 patients with N-ERD (NSAID-exacerbated respiratory disease), CRSwNP and asthma who received therapy with Omalizumab (10 f, 6 m, Ø 51 years) were included. Rhinological and pneumological parameters (NP- and ACT-score), the RSOM-31 total score with the subscales “sleep” and “emotional consequences” as well as the SF-36 were evaluated prior and after a 3-month therapy with Omalizumab.
Results The NP-score was significantly reduced after 3 months (mean 2.9 / mean 1.3; p = 0.001) and asthma control was significantly improved (mean 16.5 / 20.1; p = 0.008). The RSOM-31 total score (p = 0.001) with the subscales “sleep” (p = 0.037) and “emotional consequences” (p = 0.008) as well as the SF-36 (p = 0.001) improved 3 months after therapy with Omalizumab.
Conclusions In addition to complex favorable rhinological and pneumological effects, there is an improved quality of life and sleep after therapy with Omalizumab in patients with N-ERD.
Publication History
Article published online:
24 May 2022
© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany